Cell Salvage and Donor Blood Transfusion during Caesarean Section::A Pragmatic Multicentre Randomised Controlled Trial (SALVO) by Khan, Khalid S. et al.
 
 
Cell Salvage and Donor Blood Transfusion during
Caesarean Section:
Khan, Khalid S.; Moore, Philip; Wilson, Matthew J. A.; Hooper, Richard; Allard, Shubha;
Wrench, Ian; Beresford, Lee; Roberts, Tracy; McLoughlin, Carol; Geoghegan, James;
Daniels, Jane; Catling, Sue; Clark, Vicki; Ayuk, Paul; Robson, Stephen; Gao Smith, Fang;
Hogg, Matthew; Lanz, Doris; Dodds, Julie
DOI:
10.1371/journal.pmed.1002471
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Khan, KS, Moore, P, Wilson, MJA, Hooper, R, Allard, S, Wrench, I, Beresford, L, Roberts, T, McLoughlin, C,
Geoghegan, J, Daniels, J, Catling, S, Clark, V, Ayuk, P, Robson, S, Gao Smith, F, Hogg, M, Lanz, D & Dodds, J
2017, 'Cell Salvage and Donor Blood Transfusion during Caesarean Section: A Pragmatic Multicentre
Randomised Controlled Trial (SALVO)', PLoS Medicine, vol. 14, no. 12, e1002471.
https://doi.org/10.1371/journal.pmed.1002471
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Khan KS, Moore PAS, Wilson MJ, Hooper R, Allard S, Wrench I, et al. (2017) Cell salvage and donor blood transfusion during cesarean
section: A
pragmatic, multicentre randomised controlled trial (SALVO). PLoS Med 14(12): e1002471. https://doi. org/10.1371/journal.pmed.1002471
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
RESEARCH ARTICLE
Cell salvage and donor blood transfusion
during cesarean section: A pragmatic,
multicentre randomised controlled trial
(SALVO)
Khalid S. Khan1*, Philip A. S. Moore2, Matthew J. Wilson3, Richard Hooper4,
Shubha Allard5, Ian Wrench6, Lee Beresford4, Tracy E. Roberts7, Carol McLoughlin7,
James Geoghegan2, Jane P. Daniels8, Sue Catling9, Vicki A. Clark10, Paul Ayuk11,
Stephen Robson12, Fang Gao-Smith13, Matthew Hogg14, Doris Lanz1, Julie Dodds1,
on behalf of the SALVO study group¶
1 Women’s Health Research Unit, Barts and The London School of Medicine and Dentistry, Queen Mary
University of London, United Kingdom, 2 Birmingham Women’s Hospital, Birmingham, United Kingdom,
3 School of Health and Related Research, University of Sheffield, United Kingdom, 4 Pragmatic Clinical
Trials Unit, Centre for Primary Care and Public Health, Queen Mary University of London, United Kingdom,
5 NHS Blood and Transplant, London, United Kingdom, 6 Sheffield Teaching Hospitals NHS Foundation
Trust, Sheffield, United Kingdom, 7 Health Economics Unit, Institute of Applied Health Research, University
of Birmingham, United Kingdom, 8 Nottingham Clinical Trials Unit, University of Nottingham, United Kingdom,
9 Singleton Hospital, Swansea, United Kingdom, 10 Simpson Centre for Reproductive Health, Royal
Infirmary of Edinburgh, Edinburgh, United Kingdom, 11 Royal Victoria Infirmary, Newcastle-upon-Tyne,
United Kingdom, 12 Institute of Cellular Medicine, Newcastle University, United Kingdom, 13 Peri-operative,
Critical Care and Trauma Trials Group, University of Birmingham, United Kingdom, 14 Royal London
Hospital, Barts Health NHS Trust, London, United Kingdom
¶ Membership of the SALVO study group is provided in the Acknowledgements.
* k.s.khan@qmul.ac.uk
Abstract
Background
Excessive haemorrhage at cesarean section requires donor (allogeneic) blood transfusion.
Cell salvage may reduce this requirement.
Methods and findings
We conducted a pragmatic randomised controlled trial (at 26 obstetric units; participants
recruited from 4 June 2013 to 17 April 2016) of routine cell salvage use (intervention) versus
current standard of care without routine salvage use (control) in cesarean section among
women at risk of haemorrhage. Randomisation was stratified, using random permuted
blocks of variable sizes. In an intention-to-treat analysis, we used multivariable models,
adjusting for stratification variables and prognostic factors identified a priori, to compare
rates of donor blood transfusion (primary outcome) and fetomaternal haemorrhage2 ml in
RhD-negative women with RhD-positive babies (a secondary outcome) between groups.
Among 3,028 women randomised (2,990 analysed), 95.6% of 1,498 assigned to interven-
tion had cell salvage deployed (50.8% had salvaged blood returned; mean 259.9 ml) versus
3.9% of 1,492 assigned to control. Donor blood transfusion rate was 3.5% in the control
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group versus 2.5% in the intervention group (adjusted odds ratio [OR] 0.65, 95% confidence
interval [CI] 0.42 to 1.01, p = 0.056; adjusted risk difference −1.03, 95% CI −2.13 to 0.06). In
a planned subgroup analysis, the transfusion rate was 4.6% in women assigned to control
versus 3.0% in the intervention group among emergency cesareans (adjusted OR 0.58,
95% CI 0.34 to 0.99), whereas it was 2.2% versus 1.8% among elective cesareans
(adjusted OR 0.83, 95% CI 0.38 to 1.83) (interaction p = 0.46). No case of amniotic fluid
embolism was observed. The rate of fetomaternal haemorrhage was higher with the inter-
vention (10.5% in the control group versus 25.6% in the intervention group, adjusted OR
5.63, 95% CI 1.43 to 22.14, p = 0.013). We are unable to comment on long-term antibody
sensitisation effects.
Conclusions
The overall reduction observed in donor blood transfusion associated with the routine use of
cell salvage during cesarean section was not statistically significant.
Trial registration
This trial was prospectively registered on ISRCTN as trial number 66118656 and can be
viewed on http://www.isrctn.com/ISRCTN66118656.
Author summary
Why was this study done?
• Given that cesarean section rates are rising worldwide, the need for promoting alterna-
tives to blood transfusion in cesareans, such as harnessing the patient’s own reserves
where feasible, is well recognised.
• While cell salvage in operations outside of obstetrics has been shown to reduce the need
for donor blood transfusion, its effectiveness in cesarean section is unclear and is based
on only two small controlled trials of cell salvage in cesarean section, with imprecise and
inconclusive findings.
• Current obstetric guidelines on cell salvage have focused attention on the lack of high-
quality research, recognising that although there is potentially a place for cell salvage in
emergency blood loss during cesarean section, its use remains controversial.
What did the researchers do and find?
• We conducted a multicentre randomised controlled trial, including 3,028 women at risk
of haemorrhage during cesarean section, to test the effect of the routine use of cell sal-
vage compared to the current standard of care on the need for donor blood transfusion.
• While donor blood transfusion rates were lower in the cell salvage group than in the
control group (2.5% versus 3.5%, meaning that, on average, 1 in every 100 mothers
given cell salvage avoided a donor blood transfusion), the difference between the groups
was not statistically significant.
Randomised trial of cell salvage in caesarean section (SALVO)
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• Additionally, the study showed that in women with RhD-negative blood type who gave
birth to RhD-positive babies, cell salvage was associated with increased maternal expo-
sure to fetal blood.
What do these findings mean?
• These findings indicate that routine cell salvage does not lead to a statistically significant
reduction in donor blood transfusion rates in all women at risk of haemorrhage during
cesarean section.
Introduction
Childbirth by cesarean section is on the rise worldwide [1]. Excessive blood loss (haemor-
rhage) is an important cause of maternal death [2], emergency hysterectomy [3], and maternal
critical care admission [4] among women undergoing a cesarean birth [5]. The treatment of
major haemorrhage, in addition to optimising red cell mass and managing anaemia, includes
strategies to minimise blood loss. Donor (allogeneic) blood transfusion is employed when the
operative loss is life-threatening or when the mother has severe anaemia following arrest of
haemorrhage. Red cell concentrates used in donor transfusion are a finite, nationally pooled
resource in demand simultaneously by many clinical services [6]. Such transfusions also carry
risks for recipients [7]. To promote alternatives to donor transfusion, harnessing the patient’s
own reserves where feasible, is a recognised need [8,9].
Along with surgical expedience and medical therapy (including tranexamic acid [10,11]), the
use of intraoperative cell salvage may reduce the pressure on transfusion services. Cell salvage,
which collects, processes, and returns the woman’s own blood lost during surgery, is increas-
ingly being deployed during cesareans. In theory, it reduces the infectious and allergenic risks
associated with donor blood transfusion. It has also been shown to reduce the need for such
transfusions in a wide spectrum of surgical disciplines [12,13]. However, obstetric practitioners
remain concerned about the risk of amniotic fluid embolism and red cell isoimmunisation with
the use of cell salvage [14,15]. Evidence for its effective, safe use in obstetrics is limited [16–18],
and our systematic review [16] identified only 2 small randomised controlled trials with incon-
clusive findings [19,20]; thus, opinion about its value is not yet solidified [18].
We conducted a large, pragmatic, multicentre randomised trial to determine whether the
routine use of cell salvage during cesarean section in women at risk of haemorrhage could
safely reduce the need for donor blood transfusion in comparison to the current standard of
care, where salvage is not routinely used.
Methods
Study design and setting
The SALVO study was designed as a pragmatic, multicentre individually randomised con-
trolled trial with cost-effectiveness analysis. The study protocol was approved by the UK
National Research Ethics Committee (North West–Haydock, approval number 12/NW/0513),
and local permission was obtained in all participating obstetric units. The study protocol is
available as S1 Text and can also be accessed at https://njl-admin.nihr.ac.uk/document/
download/2007068. The trial was conducted in 26 UK obstetric units. No changes to the proto-
col design, statistical parameters, outcomes, eligibility criteria, or intervention were introduced
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during the study. Three substantial amendments to the protocol concerned changes to recruit-
ment materials and strategies as well as clarifications. The findings are reported as per CON-
SORT guidelines (S2 Text).
Participants
Our sample consisted of women who were admitted to the labour ward for delivery by emer-
gency or elective cesarean section, with an identifiable increased risk of haemorrhage, who
were at least 16 years of age, and able to understand written and spoken English for informed
consent. We defined increased risk of haemorrhage as any emergency cesarean or as an elec-
tive cesarean for any reason other than maternal preference or known breech presentation,
i.e., we excluded women undergoing an elective first cesarean due to either maternal prefer-
ence or known breech presentation. We also excluded women with contraindications to either
cell salvage or donor blood transfusion, such as active malignancy; sickle cell disease or trait;
cultural, religious, or social beliefs against donor blood transfusion; or rare antibodies restrict-
ing the use of cross-matched donor blood.
All study participants were provided with antenatal information about the study, and gave
informed consent before being enrolled. All participants admitted for elective cesarean section
gave written informed consent before enrolment. In the case of participants undergoing emer-
gency cesarean sections, either written consent was obtained before enrolment, or, if this was
not possible due to the urgency of the operation, verbal consent was obtained before enrol-
ment, and written informed consent was then sought after delivery.
Randomisation and masking
Participating women were randomised by entry into a bespoke online system, using random
permuted blocks of variable sizes to maintain allocation concealment, to either intervention or
control, at a ratio of 1:1. Randomisation was stratified by treatment centre, indication for
cesarean (emergency versus elective), placentation (abnormal versus normal), and multiple
birth (twins or more versus singleton). Classification of indication for cesarean was based on
urgency of delivery [21,22] as follows: emergency cesareans had varying levels of urgency
based on the threat or potential threat to the life of the woman or fetus, whereas elective cesare-
ans had no maternal or fetal compromise. Abnormal placentation was defined as a patholog-
ically low-lying placenta (placenta praevia) or abnormally invasive placenta (placenta accreta,
increta, or percreta) [23].
Allocation concealment with third-party randomisation helped minimise selection bias. How-
ever, given the nature of the intervention, it was not possible to blind local treatment staff to the
allocation post-randomisation, but in general the staff caring postpartum were different to those
involved in intraoperative care. Performance bias as a result of knowing the participant’s alloca-
tion could lead transfusion rates to vary. Pragmatically, the need for donor blood transfusion
postpartum was determined according to the policies of each participating hospital, and donor
blood transfusion rates and transfusion thresholds were monitored for compliance with these.
Procedures
Participants were allocated either to cesarean section with routine use of cell salvage (interven-
tion group), i.e., salvage equipment set up at the outset of cesarean to collect, process, and
return blood lost at surgery after delivery of baby, or to cesarean section with the usual stan-
dard of care (control group), i.e., without routine use of cell salvage. In life-threatening acute
haemorrhage, women were managed in line with the standard of care for such an emergency
[2,23], which potentially included the use of cell salvage in the control group.
Randomised trial of cell salvage in caesarean section (SALVO)
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The intervention was delivered by staff (anaesthetists, operating department practitioners,
midwives, or nurses as per local policy) who had been formally trained in the use of the cell sal-
vage equipment, in accordance with local procedures and requirements for competence. In
line with the pragmatic nature of the trial, no specific cell saver model was prescribed, and
both standard and continuous transfusion models were in use.
For patients randomised to the intervention, full cell saver set-up for both collection and
processing was mandated as part of the study protocol, as was the return of any volume of pro-
cessed blood. Other process factors, such as swab washing [24], leukocyte depletion filter use,
or number of suckers used, were left to local policy—although swab washing was encouraged
as it was expected to increase the volume of blood available for processing and thus for re-
transfusion.
The above process factors and adherence or non-adherence to the allocated intervention
were captured on case report forms. For participants allocated to the intervention, we docu-
mented whether non-adherence was due to technical failure of the equipment or whether cell
salvage was not set up, in violation of the protocol. For participants allocated to the control
group, we documented whether non-adherence was due to acute emergency blood loss or
whether cell salvage was set up from the beginning of the procedure, in violation of the proto-
col. As part of the continuous central trial oversight, sites with high rates of deviation were
contacted and encouraged to review their procedures and equipoise.
Participants were followed up until hospital discharge. Postnatal investigations captured the
outcomes listed below. RhD-negative women with RhD-positive babies were assessed for anti-
D dose given after delivery and exposure to fetal blood by a screening acid elution test (Klei-
hauer) to determine if additional anti-D was needed. Confirmatory flow cytometry tests were
documented for Kleihauer tests indicating a fetomaternal haemorrhage of>2 ml. If additional
anti-D was indicated or where fetomaternal haemorrhage was >4 ml, the results of repeat test-
ing undertaken after 72 hours were documented to establish clearance of fetal cells from the
maternal circulation [25]. Adverse events were monitored, investigated, classified (serious or
not; related or not), and reported to capture data on the safety of cell salvage.
Outcomes
The primary outcome was the rate of women receiving donor blood transfusion to manage
haemorrhage and its consequences, either during cesarean section or between surgery and
hospital discharge. The primary outcome was assessed at sites from medical records and subse-
quently verified by cross-checking transfusion laboratory records.
Secondary outcomes included units of blood transfused, time to first mobilisation, length of
hospital stay, pre- and postoperative serum haemoglobin, fetomaternal haemorrhage mea-
sured by Kleihauer acid elution test, maternal fatigue captured using the Multidimensional
Fatigue Inventory (MFI) [26], safety outcomes (including transfusion reactions), costs of
resources and service provision, and process outcomes (including volume of salvaged blood
returned and technical failure of cell salvage).
Analysis
A sample size of 3,050 women (1,525 per group) was planned to detect an absolute difference
in transfusion rate of 2% (5% in the standard care group, 3% in the cell salvage group, relative
risk 0.6) with a power of 80% for a 2-sided test, and a type I error rate of 5% (for rate assump-
tions see the SALVO protocol).
All analyses were performed using Stata version 12 and on an intention-to-treat basis. For
each primary and secondary outcome, we analysed all participants with non-missing data for
Randomised trial of cell salvage in caesarean section (SALVO)
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that outcome. This approach is valid if data are missing at random (MAR) [27]. Our analysis
plan specified that if more than 5% of primary outcome data were missing, we would conduct
sensitivity analyses to investigate the impact of departures from the MAR assumption on our
conclusions. Numbers of participants with missing outcome data are recorded in the results.
Univariate and multivariable regression were used to estimate crude and adjusted odds ratios
(ORs) for binary outcomes and mean differences for continuous outcomes, along with 95%
confidence intervals (CIs). Adjusted risk differences for the primary outcome were calculated
from multivariable logistic regression results using the ‘nlcom’ procedure in Stata. Number
needed to treat (NNT) was calculated as 100 divided by the risk difference in percent. ‘Time to
event’ variables were analysed using Cox proportional hazard regression to estimate the hazard
ratio (HR). Multivariable models adjusted for stratification factors (with treatment centre as a
random effect) and factors identified a priori to be prognostic for the primary outcome. The
adjusted analysis was pre-specified as primary: such adjustment typically achieves substantial
improvements in power, even when covariates are balanced [28].
We performed 2 pre-specified subgroup analyses: analyses of treatment effect by indication
for cesarean section (elective versus emergency) and by treatment centre. The first of these was
analysed by statistically testing for an interaction between indication for cesarean section and
treatment. The second was analysed by testing for a random regression coefficient for the effect
of treatment at different centres, in addition to a random intercept. Post hoc we conducted an
analysis of treatment effect by normal versus abnormal placentation, also by testing for an
interaction term.
We conducted 2 pre-specified sensitivity analyses: first, the primary analysis was redone
excluding cases of placental abruption; second, we analysed the primary outcome where return
of cell salvaged blood in the control group was reclassified as receiving a donor blood transfu-
sion. Post hoc we also restricted the second sensitivity analysis so that only participants who
received cell salvaged blood in the control group in an emergency setting were reclassified as
having received donor blood.
A cost-effectiveness analysis was carried out from the perspective of the healthcare provider
(UK National Health Service) [29] based on the principal clinical outcome of the trial, with the
results expressed as cost per unit of donor blood transfusion avoided. A decision tree model
was used that collated all the relevant resource use, cost, and outcome data collected prospec-
tively during the trial to compare the overall cost-effectiveness of cell salvage with standard
care. The resource use for both groups of the trial was estimated by prospectively evaluating
the individual components of cell salvage and standard care (bottom-up costing). Unit cost
data were then attached to the resource use. A probabilistic sensitivity analysis was carried out
to explore the effects of the inherent uncertainty in parameter estimates on model results [30].
A trial steering committee and an independent data monitoring committee provided over-
sight to the study.
Patient and public involvement
The UK National Childbirth Trust collaborated in the project by providing patient and public
input through involvement in trial design and protocol development. Prior to this trial, a sur-
vey was conducted among women who received cell salvage, showing that they perceived the
intervention as reassuring, safe, and preferable to donor blood transfusion (our primary out-
come). A patient representative was a member of the trial steering committee to provide over-
sight and advice regarding recruitment, dissemination, and general trial management. We are
planning to disseminate findings to participants in the form of a newsletter following primary
publication of these results.
Randomised trial of cell salvage in caesarean section (SALVO)
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Results
Between 4 June 2013 and 17 April 2016, 3,054 participants were recruited. The trial ended
after inclusion and treatment of the originally planned sample of participants, with the dis-
charge of the last patient on 21 April 2016.
After exclusions for eligibility and consent issues, 3,028 participants were randomly allo-
cated to either control or intervention. Of these, 1,672 were scheduled for emergency and
1,356 for elective cesarean section. After excluding further participants due to vaginal delivery
or transfer to another hospital, 1,492 participants remained in the control group and 1,498 in
the intervention group for analysis (Fig 1). Baseline characteristics of participants were similar
in the 2 groups (Table 1; additional characteristics are available in Table A in S1 Appendix).
Fig 1. Participant enrolment and follow-up (CONSORT flow diagram).
https://doi.org/10.1371/journal.pmed.1002471.g001
Randomised trial of cell salvage in caesarean section (SALVO)
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Adherence to the assigned intervention was 96.1% (1,434 participants) in the control group
and 95.6% (1,432 participants) in the cell salvage group. In the cell salvage group, 50.8% had
salvaged blood returned, averaging 259.9 ml (Table 2); there were 24 cases (1.6%) where the
salvage machine was unavailable or out of order and 42 cases (2.8%) where the machine was
simply not set up, in deviation from the protocol. In the control group, 15 participants (1.0%)
had cell salvage used in an emergency and 43 participants (2.9%) had it set up from the start of
the procedure, in deviation from the protocol.
All participants had complete data on the primary outcome and on those characteristics
specified as covariates in adjusted analyses. Overall, the transfusion rate was 3.5% in the con-
trol group versus 2.5% in the intervention group (adjusted OR 0.65, 95% CI 0.42 to 1.01,
p = 0.056; adjusted risk difference −1.03, 95% CI −2.13 to 0.06; NNT 97, at the lower limit of
95% confidence NNT was 47 and at the upper limit the number needed to harm was 1,667)
(Table 3). In the planned subgroup analysis, the transfusion rate was 4.6% in women assigned
to control versus 3.0% in those assigned to cell salvage among emergency cesarean sections
Table 1. Characteristics of participants at baseline.
Characteristic Control (n = 1,511) Cell salvage (n = 1,517)
Age at randomisation (years) 31.8 (5.8) 31.6 (5.7)
Preoperative haemoglobin (g/l) 118.1 (11.5) [19] 118.4 (11.3) [11]
Indication for cesarean1
Elective 687 (45.5%) 669 (44.1%)
Emergency 824 (54.5%) 848 (55.9%)
Multiple birth1
Singleton 1,428 (94.5%) 1,428 (94.1%)
Twins or multiple 83 (5.5%) 89 (5.9%)
Placentation1
Abnormal2 135 (8.9%) 136 (9.0%)
Normal 1,376 (91.1%) 1,381 (91.0%)
Placenta praevia 130 (8.6%) 133 (8.8%)
Abnormally invasive placenta 8 (0.5%) 4 (0.3%)
Pre-eclampsia 74 (4.9%) 69 (4.5%)
Previous emergency cesarean 602 (39.8%) 633 (41.7%)
Previous elective cesarean 241 (15.9%) 231 (15.2%)
Placental abruption 3 (0.2%) 2 (0.1%)
Ethnicity
White 1,213 (80.3%) 1,219 (80.4%)
Mixed 23 (1.5%) 14 (0.9%)
Asian or Asian British 158 (10.5%) 173 (11.4%)
Black or Black British 67 (4.4%) 71 (4.7%)
Other 50 (3.3%) 40 (2.6%)
Parity
0 571 (37.8%) 583 (38.4%)
1 556 (36.8%) 562 (37.0%)
2 240 (15.9%) 238 (15.7%)
3+ 144 (9.5%) 134 (8.8%)
Data presented are n (%) or mean (SD) [n missing].
1Used as a stratification factor in randomisation (along with treatment centre).
2Placenta praevia and/or abnormally invasive placenta.
https://doi.org/10.1371/journal.pmed.1002471.t001
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(adjusted OR 0.58, 95% CI 0.34 to 0.99), whereas it was 2.2% in women assigned to control ver-
sus 1.8% in women assigned to intervention among elective cesarean sections (adjusted OR
0.83, 95% CI 0.38 to 1.83) (interaction p = 0.46). The test for heterogeneity of treatment effect
across treatment centres (random regression coefficient for centre) was non-significant
(p = 0.09). In the exploratory subgroup analysis, the transfusion rate was 2.9% in women
assigned to control versus 1.8% in those assigned to cell salvage among cesarean sections with
normal placentation (adjusted OR 0.56, 95% CI 0.34 to 0.94), whereas it was 8.9% in women
assigned to control versus 9.6% in women assigned to intervention among cesarean sections
with abnormal placentation (adjusted OR 0.83, 95% CI 0.38 to 1.83) (interaction p = 0.28). The
planned sensitivity analysis assuming that any return of cell salvaged blood in the control
group was in place of a donor blood transfusion showed a reduction in the rate of participants
requiring donor blood transfusion from 5.6% to 2.5% (adjusted OR 0.39, 95% CI 0.26 to 0.59,
p< 0.001). A reduction was also observed when the sensitivity analysis was restricted to
Table 2. Summary of cell salvage use.
Item Control (n = 1,492) Cell salvage (n = 1,498)
Cell salvage machine set-up
Machine set up 43 (2.9%) 1,432 (95.6%)
Emergency use 15 (1.0%) 0 (0.0%)
Machine not set up 1,434 (96.1%) 42 (2.8%)
Unavailable/out of order 0 (0.0%) 24 (1.6%)
Received allocated treatment 1,434 (96.1%) 1,432 (95.6%)
If cell salvage set up (including emergency use) (n = 1,490)
Number of suckers used
1 27 (48.2%) 829 (58.1%)
2 29 (51.8%) 598 (41.9%)
Missing 2 5
Swabs washed 21 (36.8%) [1] 781 (54.8%) [6]
Size of centrifuge bowl used (ml)1 183.2 (59.2) [2] 177.1 (59.8) [37]
Leukocyte depletion filter used 25 (43.9%) [1] 782 (54.9%) [7]
Salvaged blood returned 35 (60.3%) [0] 726 (50.8%) [3]
If blood returned during cell salvage (n = 761)
Volume of blood returned to mother (ml) 288.4 (198.3) 259.9 (149.7)
If no blood returned during cell salvage (n = 726)
Reason for no return
No blood produced 14 (63.6%) 575 (88.9%)
Technical error 0 (0.0%) 25 (3.9%)
Other2 8 (36.4%) 47 (7.3%)
Missing 1 56
Data presented are n (%) or mean (SD) [n missing]. See Tables H and I in S1 Appendix for further
summaries related to swab washing. Missing observations are not included in percentage calculations.
Where variables are categorical, the number of participants with a missing value is listed in a separate row.
1Measure not applicable for sites with a continuous transfusion system only (control group: n = 22; cell
salvage group: n = 180).
2Other reasons include ‘clinical decision’ (n = 7), ‘human error’ (n = 5), ‘meconium, infection risk, or
contamination’ (n = 12), ‘minimal processed blood’ (n = 25), ‘patient declined’ (n = 2), ‘tubing trapped next to
centrifuge bowl’ (n = 1), and ‘unclear’ (n = 3).
https://doi.org/10.1371/journal.pmed.1002471.t002
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reclassifying only those who received salvaged blood in the control group for acute emergency
blood loss (4.0% versus 2.5%, adjusted OR 0.56, 95% CI 0.36 to 0.86, p = 0.008).
All secondary outcomes had less than 5% missing data, except for fetomaternal haemor-
rhage (Table 4). There were small differences between groups for time to mobilisation (median
0.74 versus 0.72 days for the control and intervention group, respectively, adjusted HR 1.11,
95% CI 1.03 to 1.19, p = 0.006) and length of hospital stay (2.131 versus 2.126 days, adjusted
HR 1.08, 95% CI 1.00 to 1.16, p = 0.050). For the subgroup of RhD-negative mothers with
RhD-positive babies, women assigned to the intervention group had a greater rate of fetoma-
ternal haemorrhage2 ml than women assigned to the control group (10.5% [n = 9] versus
25.6% [n = 21], adjusted OR 5.63, 95% CI 1.43 to 22.14, p = 0.013). When blood was returned
in this subgroup during cell salvage, 48% of participants (n = 15) experienced exposure to fetal
blood, compared to 13% (n = 6) when blood was not returned (see Table D in S1 Appendix).
There were no differences between groups in other secondary outcomes, including adverse
events. Of 18 events related to cell salvage, 16 were associated with leukocyte depletion filter
Table 3. Effect of the intervention on donor blood transfusion (the primary outcome).
Analysis Number (%) Crude analysis Adjusted analysis1
Control
(n = 1,492)
Cell salvage
(n = 1,498)
Risk
difference
percent
(95% CI)
Intervention
odds ratio
(95% CI)
p-Value Risk
difference
percent
(95% CI)
Intervention
odds ratio
(95% CI)
p-Value
Primary analysis
Received donor blood
transfusion
52 (3.5%) 37 (2.5%) −1.02 (−2.23,
0.20)
0.70 (0.46, 1.08) 0.10 −1.03 (−2.13,
0.06)
0.65 (0.42, 1.01) 0.056
Sub-group analysis by
indication for cesarean
Emergency cesarean
(n = 1,641)
37 (4.6%) 25 (3.0%) 0.58 (0.34, 0.99)
Elective cesarean (n = 1,349) 15 (2.2%) 12 (1.8%) 0.83 (0.38, 1.83)
p-Value for interaction 0.46
Sub-group analysis by
placentation2
Normal placentation
(n = 2,720)
40 (2.9%) 24 (1.8%) 0.56 (0.34, 0.94)
Abnormal placentation
(n = 270)
12 (8.9%) 13 (9.6%) 0.98 (0.42, 2.32)
p-Value for interaction 0.28
Sensitivity analysis
Excluding participants with
placental abruption (cell
salvage group: n = 2; control
group: n = 3)
51 (3.4%) 37 (2.5%) −0.95 (−2.17,
0.26)
0.72 (0.47, 1.10) 0.13 −0.97 (−2.07,
0.12)
0.67 (0.43, 1.03) 0.071
Assuming that return of cell
salvaged blood in the control
group avoided transfusions
83 (5.6%) 37 (2.5%) −3.09 (−4.50,
−1.69)
0.43 (0.29, 0.64) <0.001 −2.50 (−3.86,
−1.14)
0.39 (0.26, 0.59) <0.001
Assuming that return of cell
salvaged blood in the control
group in an emergency
avoided transfusions2
60 (4.0%) 37 (2.5%) −1.55 (−2.82,
−0.28)
0.60 (0.40, 0.92) 0.018 −1.53 (−2.72,
−0.33)
0.56 (0.36, 0.86) 0.008
1Adjusted for stratification factors (elective versus emergency cesarean section, presence of abnormal placentation, singleton versus twins or multiple
births, and treatment centre [as a random effect]) and other factors believed to be prognostic a priori (known placenta praevia and pre-eclampsia).
2Analysis was conducted post hoc.
https://doi.org/10.1371/journal.pmed.1002471.t003
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Table 4. Analysis of secondary outcomes.
Outcome Measure Control
(n = 1,492)
Cell salvage
(n = 1,498)
Crude analysis Adjusted analysis1
Intervention OR, MD, or
HR (95% CI)
p-Value Intervention OR, MD, or
HR (95% CI)
p-Value
Secondary outcomes
Units of blood
transfused2
Mean (SD) 2.65 (1.66) 2.70 (1.70) MD 0.05 (−0.67, 0.76) 0.89 MD −0.12 (−0.80, 0.57) 0.74
Time to mobilisation
(days)3,4
Median (IQR)
[n missing]
0.74 (0.45)
[49]
0.72 (0.45) [61] HR 1.07 (0.99, 1.15) 0.079 HR 1.11 (1.03, 1.19) 0.006
Length of hospital stay
(days)3,5
Median (IQR)
[n missing]
2.13 (1.41)
[24]
2.13 (1.37) [12] HR 1.04 (0.97, 1.12) 0.26 HR 1.08 (1.00, 1.16) 0.050
Safety outcomes
Postoperative
haemoglobin level (g/l)6
Mean (SD)
[n missing]
103.1 (12.1)
[47]
103.8 (12.2) [61] MD 0.74 (−0.15, 1.63) 0.10 MD 0.63 (−0.09, 1.35) 0.085
Fall in haemoglobin level
(g/l)6
Mean (SD)
[n missing]
15.0 (11.2)
[65]
14.5 (11.1) [72] MD −0.49 (−1.31, 0.33) 0.24 MD −0.68 (−1.40, 0.04) 0.066
Any adverse event
experienced7
n (%) [n missing8] 191 (12.8%)
[0]
199 (13.3%) [1] OR 1.04 (0.84, 1.29) 0.69 OR 1.02 (0.81, 1.29) 0.84
Fetomaternal
haemorrhage9
n (%) [n missing] 9 (10.5%) [33] 21 (25.6%) [51] OR 2.95 (1.26, 6.89) 0.013 OR 5.63 (1.43, 22.14) 0.013
MFI groups10
General fatigue Mean (SD)
[n missing]
12.7 (3.6) [52] 12.5 (3.6) [39] MD −0.18 (−0.47, 0.12) 0.24 MD −0.18 (−0.47, 0.11) 0.22
Physical fatigue Mean (SD)
[n missing]
12.3 (3.9) [22] 12.3 (3.9) [31] MD −0.05 (−0.36, 0.26) 0.75 MD −0.06 (−0.37, 0.25) 0.69
Reduced motivation Mean (SD)
[n missing]
9.6 (3.3) [36] 9.8 (3.4) [46] MD 0.12 (−0.15, 0.40) 0.37 MD 0.13 (−0.14, 0.40) 0.36
Reduced activity Mean (SD)
[n missing]
11.3 (3.8) [42] 11.4 (3.6) [47] MD 0.12 (−0.18, 0.43) 0.44 MD 0.12 (−0.18, 0.41) 0.45
Mental fatigue Mean (SD)
[n missing]
8.7 (3.6) [19] 8.4 (3.6) [41] MD −0.28 (−0.57, 0.01) 0.061 MD −0.30 (−0.59, −0.01) 0.043
Analysis of transfusion reaction associated with allogeneic donor blood omitted due to observing only 1 event (control group).
1Adjusted for stratification factors (elective versus emergency cesarean section, presence of abnormal placentation, singleton versus twins or multiple
births, and treatment centre [as a random effect]) and other factors believed to be prognostic a priori (known placenta praevia and pre-eclampsia).
2Analysis within the subgroup of participants who received donor blood.
3Taken from time of delivery.
4Test of proportional hazards assumption: crude analysis p = 0.67, adjusted analysis p = 0.18.
5Test of proportional hazards assumption: crude analysis p = 0.57, adjusted analysis p = 0.39.
6Adjusted analysis also adjusts for preoperative measurement, as well as the time the postoperative measurement was taken after delivery (log
transformed), with mean imputation of missing values for both covariates. Please note that the decision to adjust for the latter was made by blinded
members of the trial team after the signing off on the statistical analysis plan.
7See Tables E–G in S1 Appendix for further details on adverse events, adverse reactions, and serious adverse events.
8Missing observations are not included in percentage calculations.
9Measured by Kleihauer test and dichotomised into a result of <2 ml versus2 ml. Analysis is within the subgroup of 270 RhD-negative participants with
RhD-positive babies, of whom 252 had a Kleihauer test (119 in the control group, 133 in the cell salvage group). This measure was set to missing where
results were not categorisable, e.g., where Kleihauer result was reported as <4 ml (control group: n = 25; cell salvage group: n = 42).
10Sum of MFI statement scores (where participants indicate level of agreement with a statement between 1 and 5) within fatigue categories. Higher scores
indicate more fatigue.
HR, hazard ratio; MD, mean difference; MFI, Multidimensional Fatigue Inventory; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1002471.t004
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use. Two serious adverse reactions were reported: one patient experienced tachycardia and dif-
ficulty breathing following re-transfusion of cell salvaged blood, and another patient experi-
enced sudden hypotension after transfusion of 600 ml of cell salvaged blood. Both events were
classed by the local investigator as life-threatening and potentially related to the use of cell sal-
vage, in particular to the use of a leukocyte depletion filter (which was not mandated by the
study protocol). In both instances, patients recovered fully after cell salvage was discontinued.
There was not a single case of amniotic fluid embolism in any instance of cell salvage use, with
or without leukocyte depletion filters (details of adverse events are available in Tables E–G in
S1 Appendix).
The result of the cost-effectiveness analysis, based on the intention-to-treat analysis, showed
an incremental cost-effectiveness ratio (ICER) of £8,110 (US$10,303; €9,711) per transfusion
avoided for cell salvage compared to standard care. The probabilistic sensitivity analysis shows
that although cell salvage was more effective than standard care for avoiding donor blood
transfusion, it is uncertain whether it was less or more costly than standard care. Overall, if a
decision-maker was willing to pay £50,000 (US$63,520; €59,869) to avoid a donor blood trans-
fusion, the probability of cell salvage being cost-effective was 62% (see S1 Appendix for more
detailed data).
Discussion
This large, pragmatic, multicentre randomised trial showed that the routine use of cell salvage
during cesarean section did not lead to a statistically significant reduction in the rate of donor
blood transfusion in all women at risk of haemorrhage during cesarean section. Cell salvage
was associated with increased maternal exposure to fetal blood among RhD-negative mothers.
No other clinically relevant differences were observed in secondary outcomes. No cases of
amniotic fluid embolism were observed, with or without leukocyte depletion filters. The cost-
effectiveness of cell salvage is uncertain.
To our knowledge, our study is the largest randomised controlled trial in the area of cell sal-
vage in obstetrics, and the only large-scale exploration of the clinical effectiveness and cost-
effectiveness of cell salvage in cesarean section. It was prospectively registered, robustly con-
ducted, independently monitored, rigorously analysed, and transparently reported. We
recruited to target with independent data monitoring, had minimal patient or data loss, and
achieved comparability at baseline. Compliance with assignment was generally excellent, but
the deployment of cell salvage in the control group was a weakness as it could have potentially
averted the use of donor transfusion, reducing the control event rate. We could not ethically
prevent such action in emergencies, but we performed a sensitivity analysis reclassifying such
cases as having experienced the primary outcome (donor blood transfusion), which showed an
effect consistent in direction with the main result. Our audit to evaluate the risk of perfor-
mance bias did not show imbalance in compliance with local transfusion policies. Our primary
analysis followed the a priori statistical analysis plan, written before unblinding the rando-
mised allocation, as agreed upon with our trial steering and data monitoring committees. It
adjusted for the variables pre-specified. The usual rule of thumb for sample size in multivari-
able logistic regression of 10 cases per variable [31] was met in the adjusted analysis model.
These methodological features should provide confidence in the validity and reliability of the
findings. The diversity of our sample, in terms of cesarean indication, age, ethnicity, and geo-
graphic spread across many treatment centres, adds to generalisability. A p-value that is in the
region of 0.05, regardless of the side of the significance threshold on which it lies, deserves
careful consideration. It would be incorrect to conclude that the addition of further data
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would push the p-value below the threshold [32]. We believe our observations can justifiably
be classed as modest [32], but not certain, evidence that can be useful in decision-making.
Our finding concerning the safety of cell salvage in cesarean sections shows that concerns
about the risk of amniotic fluid embolism should not be a barrier to its deployment. The 2 seri-
ous adverse reactions observed are in keeping with known effects of leukocyte depletion filters
[33]. If cell salvage is to be used, avoidance of these filters should be considered in order to
reduce the risk of adverse reactions. Our finding concerning fetomaternal haemorrhage should
be interpreted with caution. There were fewer than 10 events per variable in the model. This
was in part because of large rates of missing data. Sensitivity analyses that assume worst- or
best-case scenarios would inevitably give divergent results in this situation. It is debatable
whether one could rely on accurately imputing missing outcomes from the data that were
available. Despite these limitations, the risk of maternal exposure to fetal blood is a key issue
for policies concerning obstetric use of cell salvage. There is a need to put mechanisms in place
for maximising adherence to anti-D prophylaxis guidelines for the prevention of RhD red cell
isoimmunisation. UK guidelines recommend a dose of 1,500 IU of anti-D following birth of
an RhD-positive baby to an RhD-negative mother after cell salvage, with tests for fetomaternal
haemorrhage to check if additional doses are needed [15].
The findings around the secondary outcome of fetomaternal haemorrhage highlight a need
not only for long-term vigilance but also for research to determine the efficacy of anti-D pro-
phylaxis, given that our study does not provide long-term follow-up data on RhD-negative
mothers. The UK Serious Hazards of Transfusion haemovigilance scheme has flagged up the
risk of sensitisation in women who do appear to have received appropriate prophylaxis [34].
Investigation is needed to determine if greater amounts of routine anti-D administration are
required where cell salvage has been used in RhD-negative mothers. Additionally, the rate and
severity of red cell isoimmunisation to rarer, non-RhD antibodies following cell salvage is
unknown [16] and merits further study.
Concerning policy-making for deployment of cell salvage, its cost-effectiveness is going to
be an issue for funders of services. Even if routine use of cell salvage was shown to be clinically
effective, it is currently unlikely to be considered cost-effective for routine use in all indications
for cesarean sections. Emergency cesarean sections have higher blood loss, and in these, cell
salvage is not currently in routine use in practice. The potential for benefit in this group merits
confirmation through additional research. The future benefit will depend on the extent to
which cell salvage represents good value for money when changes occur in the rate of cesarean
section, the rate of donor blood transfusion, the quality of the supply chain of donor blood for
transfusion, and the contingency to address shocks on the supply of donor blood. Further
delineation of cost-effectiveness in high-risk subgroups, particularly in settings with a limited
supply of blood for transfusion, will be helpful in guiding decision-making.
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